Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgery patients may need fewer transfusions with EPO and iron combo

NCT ID NCT04141631

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving erythropoietin (EPO) and an iron injection before heart surgery could lower the number of patients needing blood transfusions. 128 adults scheduled for heart surgery who were at high risk of transfusion took part. The approach aimed to boost hemoglobin levels and guide transfusions using a measure of oxygen in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
erythropoietin (EPO) and ferric carboxymaltose (iron injection)
What this could lead to
If successful, this approach could reduce the need for blood transfusions in heart surgery patients, lowering risks and costs.
What could go wrong
This is a completed study with 128 patients, so results are limited. The strategy may not work for all patients or settings, and there are risks like allergic reactions to the drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

128 people

The number who actually took part.

Started

Jan 2020

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Scheduled Cardiac surgery for more than 24 hours * High risk of perioperative transfusion defined by a TRUST Score ≥ 3 * Veno-Venous catheter in Superior vena cava territory * Patient Affiliate or beneficiary of social security * Collection on free, informed and written consent Exclusion Criteria: * EPO and FCM contraindication * Patients already treated by EPO at the time of inclusion * Non controlled Infectious endocarditis defined by ESC guidelines 2015 * Patients including in an other research * Patients whose physical and/or psychological health is severely impaired and who, according to the investigator, may affect the participant's compliance with the study. * Patients deprived from his rights (guardianship or tutelage measure) * Patients who refuses to sign the consent * pregnant or lactating woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac surgery Perioperative anemia Transfusion

Contacts and locations

Locations

  • DEpartement d'anesthésie et réanimation D - Arnaud de Villeneuve

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.